福建中医药大学附属人民医院,福建省福州市台江区八一七中路602号,350004
Ybinhua2022@163.com,(0591)86250108
收稿:2022-07-28,
修回:2022-11-12,
纸质出版:2023-01-17
移动端阅览
叶彬华,江铭倩,邱晨等.莲实健脾食疗方干预糖耐量受损脾虚不运证患者36例临床观察[J].中医杂志,2023,64(02):153-158.
YE Binhua,JIANG Mingqian,QIU Chen,et al.Clinical Observation on Lianshi Jianpi Dietary Formula (莲实健脾食疗方) on Impaired Glucose Tolerance with Failure of Transportation due to Spleen Deficiency Pattern in 36 Cases[J].Journal of Traditional Chinese Medicine,2023,64(02):153-158.
叶彬华,江铭倩,邱晨等.莲实健脾食疗方干预糖耐量受损脾虚不运证患者36例临床观察[J].中医杂志,2023,64(02):153-158. DOI: 10.13288/j.11-2166/r.2023.02.009.
YE Binhua,JIANG Mingqian,QIU Chen,et al.Clinical Observation on Lianshi Jianpi Dietary Formula (莲实健脾食疗方) on Impaired Glucose Tolerance with Failure of Transportation due to Spleen Deficiency Pattern in 36 Cases[J].Journal of Traditional Chinese Medicine,2023,64(02):153-158. DOI: 10.13288/j.11-2166/r.2023.02.009.
目的
2
观察莲实健脾食疗方干预糖耐量受损脾虚不运证患者的临床疗效及可能作用机制。
方法
2
将78例糖耐量受损脾虚不运证患者随机分为治疗组与对照组各39例。两组均予相同的营养及生活方式指导,治疗组每日早餐为莲实健脾食疗方+鸡蛋,对照组每日早餐为馒头+鸡蛋,干预周期均为90天。治疗前后检测糖代谢相关指标[包括空腹血糖(FPG)、葡萄糖负荷后2 h血糖(OGTT 2hPG)、糖化血红蛋白(HbA1c)],人体测量学指标包括[体重、体重指数(BMI)、腰围、体脂率、肌肉量],胰岛功能指标[包括空腹胰岛素(FINS)、葡萄糖负荷后2h胰岛素(OGTT 2h INS)、胰岛素抵抗指数(HOMA-IR)、胰岛素β细胞功能指数(HOMA-β)],糖脂代谢相关因子[包括成纤维细胞生长因子21(FGF21)、游离脂肪酸(FFA)、胰高糖素样肽1(GLP-1)]水平,干预后判定临床疗效。
结果
2
干预期间共脱落6例患者,最终纳入分析两组各36例。治疗组患者临床缓解率为61.1%(22/36),明显高于对照组的27.8%(10/36,
P
<0.05)。与治疗前比较,治疗组OGTT 2hPG、体重、BMI、腰围、体脂率、HOMA-IR、FGF21、FFA降低,肌肉量、GLP-1升高(
P
<0.05);对照组FGF21、BMI、腰围降低,GLP-1升高(
P
<0.05)。治疗后组间比较,治疗组OGTT 2hPG、HOMA-IR、体重、BMI、腰围、体脂率、FGF21、肌肉量、GLP-1水平改善均优于对照组(
P
<0.05)。
结论
2
莲实健脾食疗方可改善糖耐量受损脾虚不运证患者糖代谢及胰岛素抵抗,其机制可能与下调FGF21、上调GLP-1水平有关。
Objective
2
To evaluate the clinical efficacy and the possible mechanism of
Lianshi Jianpi Dietary Formula
(莲实健脾食疗, LJDF) on impaired glucose tolerance (IGT) with failure of transportation due to spleen deficiency pattern.
Methods
2
Seventy-eight patients with IGT and failure of transportation due to spleen deficiency pattern were randomly divided into test group and control group, with 39 cases in each group. Both groups were given the same nutrition and lifestyle guidance. The breakfast of the test group was LJDF plus an egg, and that of the control group was steamed bread plus an egg, both for 90 days. The glucose metabolism-related levels including fasting blood glucose (FPG), 2 h plasma glucose after an oral glucose tolerance test (OGTT 2hPG), glycosylated hemoglobin (HbA1c), anthropometric indicators including weight, body mass index (BMI), waist circumference, body fat percentage, muscle mass, islet function indicators including fasting insulin (FINS), 2 h insulin after an oral glucose tolerance test (OGTT 2 h INS), homeostatic model assessment for insulin resistance (HOMA-IR), homeostasis model assessment of β-cell function (HOMA-β), glucolipid metabolism-related factors including fibroblast growth factor 21 (FGF21, FFA), free fatty acid (FFA), and glucagon-like peptide 1 (GLP-1) were observed before and after treatment in the two groups. The clinical efficacy was judged after the treatment.
Results
2
Six patients dropped out, and 36 cases in each group were included in the final analysis. The clinical remission rate of patients in the test group was 61.1% (22/36), which was significantly better than 27.8% (10/36) in the control group (
P
<0.05). After treatment, OGTT 2hPG, body weight, BMI, waist circumference, body fat percentage, HOMA-IR, FGF21, and FFA in the test group decreased, while muscle mass and GLP-1 increased (
P
<0.05); FGF21, BMI, waist circumference in the control group decreased, while GLP-1 increased (
P
<0.05). When compared between groups, much more improvements were seen in the test group than the control group regarding OGTT 2hPG, HOMA-IR, body weight, BMI, waist circumference, body fat percentage, FGF21, muscle mass, and GLP-1 levels (
P
<0.05).
Conclusion
2
LJDF can improve glucose metabolism and insulin resistance in the treatment of IGT patients with failure of transportation due to spleen deficiency pattern. The mechanism may be related to down-regulating FGF21 and increasing GLP-1 levels.
中华医学会糖尿病学分会 . 中国2型糖尿病防治指南(2020年版) [J]. 国际内分泌代谢杂志 , 2021 , 41 ( 5 ): 482 - 548 .
胥雨成 , 金智生 . 基于脾瘅理论探讨早期糖尿病 [J]. 实用中医内科杂志 , 2021 , 35 ( 9 ): 18 - 20 .
ALBERTI KG , ZIMMET PZ . Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation [J]. Diabet Med , 1998 , 15 ( 7 ): 539 - 553 .
国家市场监督管理总局 , 国家标准化管理委员会 . 中医临床诊疗术语 第2部分:证候 [S]. 北京 : 中国标准出版社 , 2021 : 178 .
方朝晖 , 仝小林 , 段俊国 , 等 . 糖尿病前期中医药循证临床实践指南 [J]. 中医杂志 , 2017 , 58 ( 3 ): 268 - 272 .
史周华 , 何雁 . 中医药统计学与软件应用 [M]. 2版 . 北京 : 中国中医药出版社 , 2017 : 268 .
GARBER CE , BLISSMER B , DESCHENES MR , et al . American college of sports medicine position stand. quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise [J]. Med Sci Sports Exerc , 2011 , 43 ( 7 ): 1334 - 1359 .
中华医学会内分泌学分会 , 中华医学会糖尿病学分会 , 中国医师协会内分泌代谢科医师分会 , 等 . 中国成人糖尿病前期干预的专家共识 [J]. 中华内分泌代谢杂志 , 2020 , 36 ( 5 ): 371 - 380 .
郑腊萍 . 从脾失健运论治糖耐量异常 [J]. 中医药临床杂志 , 2020 , 32 ( 7 ): 1225 - 1228 .
罗源 , 方朝晖 , 舒仪琼 . 糖尿病前期“从脾论治”的理论探讨 [J]. 中医药临床杂志 , 2014 , 26 ( 3 ): 322 - 324 .
杨月欣 . 中国食物成分表 [M]. 6版 . 北京 : 北京大学医学出版社 , 2020 : 13 - 83 .
中国营养学会 . 中国居民膳食指南2022 [M]. 北京 : 人民卫生出版社 , 2022 : 48 .
施继尧 , 王蒙 , 吴弢 . 莲子心的化学成分及生物活性研究进展 [J]. 中医药导报 , 2018 , 24 ( 21 ): 105 - 108 .
王琦 . 莲子抗性淀粉降血糖功效及其机理研究 [D]. 福州 : 福建农林大学 , 2018 .
WU CY , WANG H , HE XX , et al . The hypoglycemic and antioxidant effects of polysaccharides from the petioles and pedicels of Euryale ferox Salisb. on alloxan-induced hyperglycemic mice [J]. Food Funct , 2017 , 8 ( 10 ): 3803 - 3813 .
YUAN H , MENG S , WANG G , et al . Hypoglycemic effect of triterpenoid-rich extracts from Euryale ferox shell on normal and streptozotocin-diabetic mice [J]. Pak J Pharm Sci , 2014 , 27 ( 4 ): 859 - 864 .
沈佳奇 , 李志 , 周棱波 , 等 . 薏苡仁油主要成分及其功能性研究进展 [J]. 中国油脂 , 2020 , 45 ( 8 ): 90 - 95 .
赵艳威 , 孙静 , 李玲 , 等 . 黑豆皮花青素对2型糖尿病大鼠氧化应激信号传导通路DAG-PKC的影响 [J]. 中药药理与临床 , 2012 , 28 ( 6 ): 27 - 29 .
FLIPPO KH , POTTHOFF MJ . Metabolic messengers: FGF21 [J]. Nat Metab , 2021 , 3 ( 3 ): 309 - 317 .
HEIDARI Z , HASANPOUR M . The serum fibroblast growth factor 21 is correlated with retinopathy in patients with type 2 diabetes mellitus [J]. Diabetes Metab Syndr , 2021 , 15 ( 6 ): 102296 . doi: 10.1016/j.dsx. 2021. 102296 http://dx.doi.org/10.1016/j.dsx.2021.102296 .
MASELLI DB , CAMILLERI M . Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity [J]. Adv Exp Med Biol , 2021 , 1307 : 171 - 192 . doi: 10.1007/5584_2020_496 http://dx.doi.org/10.1007/5584_2020_496 .
PAN Q , LIN S , LI Y , et al . A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis [J]. EBioMedicine , 2021 , 63 : 103202 . doi: 10.1016/j.ebiom.2020.103202 http://dx.doi.org/10.1016/j.ebiom.2020.103202 .
程万里 , 王岚 , 孙红霞 , 等 . 糖耐量受损患者肝脏过氧化物酶体脂代谢情况分析 [J]. 山西医药杂志(下半月版) , 2013 , 42 ( 16 ): 863 - 865 .
0
浏览量
3
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号